Ongoing clinical trials (NCT04666688) will provide important information regarding the safety and effectiveness of Gal-9 blockade, potentially helping the translation of Gal-9 targeting intervention for GVHD patients.79 This evidence concerns the gene LGALS9 and graft versus host disease.